Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

MetaStat To Present at SeeThruEquity Conference in New York City on May 28

Presentation to Be Webcast

BOSTON, MA / ACCESSWIRE / May 20, 2015 / MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will present at the SeeThruEquity Fourth Annual Microcap Investor Conference in New York City on Thursday, May 28, 2015 at 10:30 AM ET.

Oscar L. Bronsther, M.D., CEO of MetaStat, will be reviewing the Company's business and growth strategy during the presentation. Dr. Bronsther will also be available to meet with members of the investment community during one-on-one sessions being held at the conference. Members of the investment community interested in meeting with management that day can contact their representative at SeeThruEquity, or Tom Caden of DGI at 212-825-3210.

The presentation will be webcast live and archived at the following link: http://wsw.com/webcast/seethru11/mtst

About MetaStat, Inc.

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast(TM) and MenaCalc(TM) assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat's testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Contact:

Media:
Dian Griesel Int'l. for MetaStat
Susan Forman, 212-825-3210
sforman@dgicomm.com 

or

Investors:
MetaStat, Inc.
Douglas Hamilton, CFO, (917) 597-4164
Dhamilton@metastat.com

SOURCE: MetaStat, Inc.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.